As Esperion Therapeutics INC (ESPR) Share Price Rose, Meditor Group LTD Has Raised by $86.45 Million Its Holding

February 24, 2018 - By Adrian Erickson

Investors sentiment increased to 1.67 in Q3 2017. Its up 0.45, from 1.22 in 2017Q2. It is positive, as 11 investors sold ESPR shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 22.73 million shares or 17.55% more from 19.33 million shares in 2017Q2 were reported. Aisling Cap Ltd Liability invested in 837,125 shares. 24,970 are held by Alliancebernstein Ltd Partnership. Northern Tru Corporation reported 0.01% stake. Iguana Healthcare Mngmt Ltd Liability holds 150,000 shares. Blackrock reported 1.52M shares stake. Royal Bancorp Of Canada holds 3,183 shares or 0% of its portfolio. State Of New Jersey Common Pension Fund D has 36,875 shares for 0.01% of their portfolio. Rhenman And Ptnrs Asset Ab reported 2% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). 189,899 were reported by Amundi Pioneer Asset Inc. Pinnacle Assocs Limited reported 717,813 shares stake. Partner Fund Mngmt Limited Partnership has invested 0.54% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Bailard holds 63,300 shares or 0.24% of its portfolio. Tudor Inv Et Al owns 0.05% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 42,954 shares. Laurion Mgmt LP reported 10,800 shares. Meeder Asset Mngmt Inc stated it has 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Meditor Group Ltd increased its stake in Esperion Therapeutics Inc (ESPR) by 305.47% based on its latest 2017Q3 regulatory filing with the SEC. Meditor Group Ltd bought 1.73M shares as the company’s stock rose 33.24% with the market. The institutional investor held 2.29 million shares of the health care company at the end of 2017Q3, valued at $115.02M, up from 566,000 at the end of the previous reported quarter. Meditor Group Ltd who had been investing in Esperion Therapeutics Inc for a number of months, seems to be bullish on the $2.09B market cap company. The stock increased 1.23% or $0.96 during the last trading session, reaching $78.9. About 282,956 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 133.75% since February 24, 2017 and is uptrending. It has outperformed by 117.05% the S&P500.

Meditor Group Ltd, which manages about $658.73M US Long portfolio, decreased its stake in Wisdomtree India Earnings Fund (EPI) by 230,000 shares to 400,000 shares, valued at $10.07 million in 2017Q3, according to the filing.

Another recent and important Esperion Therapeutics, Inc. (NASDAQ:ESPR) news was published by Bloomberg.com which published an article titled: “Esperion Targets $10 a Day for Heart Pill to Undercut Rivals” on February 23, 2018.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 10 have Buy rating, 0 Sell and 8 Hold. Therefore 56% are positive. Esperion Therapeutics had 56 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Neutral” rating given on Monday, November 14 by Citigroup. The firm has “Hold” rating given on Monday, January 22 by Citigroup. Needham upgraded Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Monday, August 10. Needham has “Buy” rating and $130.0 target. The company was maintained on Tuesday, October 3 by Northland Capital. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Buy” rating given on Wednesday, January 17 by UBS. The firm has “Buy” rating given on Monday, October 26 by WallachBeth Capital. The stock has “Neutral” rating by JP Morgan on Wednesday, February 21. JP Morgan downgraded Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Wednesday, June 29. JP Morgan has “Neutral” rating and $15 target. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Overweight” rating by Barclays Capital on Wednesday, February 24. The firm earned “Outperform” rating on Friday, November 6 by RBC Capital Markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: